阿司匹林联合氯吡格雷治疗急性脑梗死的疗效研究

Study on efficacy of aspirin combined with clopidogrel in the treatment of acute cerebral infarction

目的分析急性脑梗死患者采用阿司匹林联合氯吡格雷治疗的效果。方法100例急性脑梗死患者,随机分为试验组和对照组,每组50例。对照组患者采用阿司匹林治疗,试验组患者采用阿司匹林联合氯吡格雷治疗。比较两组患者不良反应发生情况,治疗前后美国国立卫生研究院卒中量表(NIHSS)评分和改良Rankin量表(mRS)评分。结果试验组患者的不良反应发生率为4.00%,低于对照组的18.00%,差异具有统计学意义(P<0.05)。治疗前,两组患者的NIHSS评分和mRS评分比较差异均无统计学意义(P>0.05);治疗后,试验组患者的NIHSS评分(5.75±1.25)分、mRS评分(1.54±0.34)分均低于对照组的(8.62±1.28)、(2.27±0.54)分,差异具有统计学意义(P<0.05)。结论阿司匹林联合氯吡格雷治疗急性脑梗死的临床效果显著,可显著改善患者的临床症状,同时不良反应较少,具有较高的安全性,可改善患者的神经缺损情况,预后更佳,优越性更强,值得推广至临床。

Objective To analyze the effect of aspirin combined with clopidogrel in the treatment of acute cerebral infarction.Methods A total of 100 patients with acute cerebral infarction were randomly divided into experimental group and control group,with 50 cases in each group.Patients in the control group were treated with aspirin,and patients in the experimental group were treated with aspirin combined with clopidogrel.The incidence of adverse reactions,the National Institutes of Health Stroke Scale(NIHSS)score and the modified Rankin Scale(mRS)score before and after treatment were compared between the two groups.Results The incidence of adverse reactions in the experimental group was 4.00%,which was lower than 18.00%in the control group,and the difference was statistically significant(P<0.05).Before treatment,there was no statistically significant difference in NIHSS score and mRS score between the two groups(P>0.05).After treatment,the NIHSS score(5.75±1.25)points and mRS score(1.54±0.34)points of the experimental group were lower than(8.62±1.28)and(2.27±0.54)points of the control group,and the differences were all statistically significant(P<0.05).Conclusion The clinical effect of aspirin combined with clopidogrel in the treatment of acute cerebral infarction is remarkable,which can significantly improve the clinical symptoms of patients with few adverse effects and high safety,and can improve the neurological deficit of patients with better prognosis and superiority,which is worthy clinical promotion.